Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
Open Access
- 24 June 2010
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 2 (3) , 20
Abstract
Introduction: Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dementia and cognitively healthy elderly individuals, and to investigate their relationship with established CSF biomarkers for Alzheimer's disease. Methods: CSF was collected from 38 individuals with AD dementia and 34 cognitively healthy elderly individuals. The CSF was analyzed for MMP-1, MMP-3, MMP-9, TIMP-1, β-amyloid1-42 (Aβ42), total tau protein (T-tau) and phosphorylated tau protein (P-tau). MMP/TIMP-1 ratios were calculated. APOE genotype was determined for the participants. Results: AD patients had higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals. In AD patients, the MMP-9/TIMP-1 ratio correlated with CSF T-tau, a marker of neurodegeneration. Interestingly, the cognitively healthy individuals with risk markers for future AD, i.e. AD-supportive CSF biomarker levels of T-tau, P-tau and Aβ42 or the presence of the APOE ε4 allele, had higher CSF MMP-3 and MMP-9 levels and higher CSF MMP-3/TIMP-1 ratios compared to the healthy individuals without risk markers. The CSF levels of MMP-3 and -9 in the control group also correlated with the CSF T-tau and P-tau levels. Conclusions: This study indicates that MMP-3 and MMP-9 might be involved in early pathogenesis of AD and that MMPs could be associated with neuronal degeneration and formation of neurofibrillary tangles even prior to development of overt cognitive dysfunction.Keywords
This publication has 40 references indexed in Scilit:
- Matrix Metalloprotease-9 Inhibition Improves Amyloid β-Mediated Cognitive Impairment and Neurotoxicity in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Matrix metalloproteinases and their multiple roles in neurodegenerative diseasesThe Lancet Neurology, 2009
- SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's DiseaseBrain Pathology, 2008
- Alzheimer's diseaseThe Lancet, 2006
- Tissue inhibitor of metalloproteinase (TIMP)‐1: The TIMPed balance of matrix metalloproteinases in the central nervous systemJournal of Neuroscience Research, 2003
- Metalloproteinases in biology and pathology of the nervous systemNature Reviews Neuroscience, 2001
- Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain.2001
- Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brainActa Neuropathologica, 2000
- Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40)Journal of Neuroscience, 1996
- Increased Production of Matrix Metalloproteinases in Enriched Astrocyte and Mixed Hippocampal Cultures Treated with β‐Amyloid PeptidesJournal of Neurochemistry, 1996